NASDAQ:CARM Carisma Therapeutics Q1 2025 Earnings Report $0.0001 0.00 (0.00%) As of 12:41 PM Eastern ProfileEarnings HistoryForecast Carisma Therapeutics EPS ResultsActual EPS-$0.22Consensus EPS -$0.17Beat/MissMissed by -$0.05One Year Ago EPSN/ACarisma Therapeutics Revenue ResultsActual Revenue$3.65 millionExpected Revenue$2.47 millionBeat/MissBeat by +$1.19 millionYoY Revenue GrowthN/ACarisma Therapeutics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time6:00PM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Carisma Therapeutics Earnings HeadlinesCarmila: 2025 Annual ResultsFebruary 18, 2026 | businesswire.comCarisma Therapeutics announces Nasdaq delisting, SEC deregistrationDecember 6, 2025 | msn.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.June 1 at 1:00 AM | Brownstone Research (Ad)Carisma Announces Delisting from Nasdaq and SEC DeregistrationDecember 5, 2025 | prnewswire.comCarisma Therapeutics Announces Executive Terminations and Wind-DownOctober 17, 2025 | msn.comCarisma Therapeutics stock plunges after Nasdaq delisting noticeOctober 10, 2025 | investing.comSee More Carisma Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Carisma Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your email. Email Address About Carisma TherapeuticsCarisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells. The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies. Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.View Carisma Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameMarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
